Getinge AB's 2025 earnings surge past expectations, lifting stock prices

Getinge AB has delivered stronger-than-expected results for 2025, outperforming market forecasts. The medical technology firm saw its share price climb on Nasdaq Stockholm after reporting solid revenue growth and improved profitability. Investors have taken note as the company continues to thrive in a sector known for stability.

The company's success stems from higher sales volumes and price increases in its intensive care division. Despite global supply chain pressures, Getinge managed to keep its margins steady. This resilience has reinforced confidence among analysts, who now predict further gains.

Getinge is well-placed to benefit from long-term trends, including an ageing population and growing demand for critical care solutions. Its ongoing investment in research and development ensures it stays ahead of competitors. Looking ahead, the firm expects new product launches and continued expansion in 2026.

Recent analyst reports, including one from Pareto on 20 March, maintain a 'buy' rating with a target price of 235 SEK. Insider purchases have further bolstered market optimism, though no updated stock performance data is available beyond the initial results announcement.

Getinge's strong 2025 performance has lifted its stock and prompted upward revisions in analyst forecasts. The company's focus on innovation and its position in a stable industry suggest steady growth ahead. With new products on the horizon, investors remain watchful for further developments in 2026.